Aarti Drugs · NSE: AARTIDRUGS · BSE: 524348
Q2 FY22 results · Jul–Sep 2021
Aarti Drugs reported revenue from operations of ₹579.62 crore (up 0.3% from Q2 FY21) and net profit of ₹42.58 crore (down 43.4% from Q2 FY21) for Q2 FY22 (Jul–Sep 2021), on a consolidated basis.
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 579.62 | 578.11 | +0.3% | 579.95 | −0.1% |
| Other income | 0.08 | 0.29 | −72.4% | 1.62 | −95.1% |
| Total income | 579.70 | 578.40 | +0.2% | 581.57 | −0.3% |
| Profit before tax | 56.08 | 97.12 | −42.3% | 64.68 | −13.3% |
| Net profit for the period | 42.58 | 75.27 | −43.4% | 48.81 | −12.8% |
| Attributable to shareholders of the company | 42.59 | 75.27 | −43.4% | 48.81 | −12.7% |
| EPS, basic (₹) | 4.60 | 32.30 | not comparable | 5.25 | −12.4% |
| Net margin (%) | 7.3 | 13.0 | 8.4 |
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 510.70 | 515.16 | −0.9% | 505.79 | +1.0% |
| Other income | 0.89 | 0.26 | +242.3% | 1.64 | −45.7% |
| Total income | 511.59 | 515.42 | −0.7% | 507.43 | +0.8% |
| Profit before tax | 53.11 | 90.28 | −41.2% | 60.04 | −11.5% |
| Net profit for the period | 40.61 | 69.78 | −41.8% | 45.54 | −10.8% |
| EPS, basic (₹) | 4.39 | 29.95 | not comparable | 4.90 | −10.4% |
| Net margin (%) | 8.0 | 13.5 | 9.0 |
Consolidated
- Filed with BSE
- 28 Oct 2021, 15:47 IST
- Board meeting
- 27 Oct 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 28 Oct 2021, 15:47 IST
- Board meeting
- 27 Oct 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Audited
- Source
- XBRL filing on BSE